fda compounding semaglutide crackdown october 2025 Compounded GLP-1s: Why doctors worry and the is cracking down FDA Intensifies Crackdown on GLP-1

GLP1 therapies have become central to the management of type 2 diabetes and chronic weight conditions linked to obesity

Fiscal 2025 Adjusted EBITDA Guidance: $21 million to $24 million

If you or a loved one lived or worked near the Smyrna Sterigenics facility and have been diagnosed with cancer or another EtO-related illness, you may be eligible to file an Ethylene Oxide Lawsuit

The CEO of the Jos Andres restaurant group recently said his team is experimenting with mushroom-based drinks in places where psychedelics are legal

NMB, neuromedin B

However, it is important to consider the value that Temu brings to your organization